American Journal of Hematology · 2007 · 22 citations · 8 references
MedicineInternal MedicinePharmacotherapyImmunopharmacotherapyImmunotherapyRheumatologyEdemaPleural DiseaseFunctional Status ManagementFunctional Status MonitoringTherapeutic Targeting Of AmyloidVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor Signaling
Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.
8
Vascular endothelial growth factor (VEGF) and its receptors
Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch et al. · The FASEB Journal · 1999 · 3.5K citations
Medicine, Cell Biology, Oncology +17
Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2002 · 1.7K citations
Medicine, Oncology, Pharmacotherapy +13
Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod et al. · Journal of Clinical Oncology · 2005 · 933 citations · Full text
Medicine, Oncology, Pharmacotherapy +16